Outcomes of iTind Treatment for Benign Prostatic Hyperplasia at a Single UK Institution

Purpose Benign prostatic hyperplasia (BPH) is a prevalent cause of lower urinary tract symptoms (LUTS) in aging men. While transurethral resection of the prostate (TURP) remains the gold standard, its associated morbidity—particularly ejaculatory dysfunction—has driven interest in minimally invasive surgical therapies (MISTs). The temporary implantable nitinol device (iTind) is designed to relieve obstruction while preserving sexual function. Methods We retrospectively analysed 41 patients who underwent iTind implantation between January 2022 and September 2025 at a UK tertiary BPH centre. Pre- and post-operative outcomes included International Prostate Symptom Score (IPSS), quality of life (QoL), maximum urinary flow rate (Qmax), post-void residual (PVR), complications, and ejaculatory function. Statistical analysis was performed using non-parametric tests where appropriate. Results Mean patient age was 52.2 ± 13.8 years, with a mean prostate volume of 33.8 ± 12.0 cc. Significant improvements were observed in IPSS, QoL, Qmax, and PVR at 0–6 and 6–12 months (all p < 0.001). Median follow-up was 15 months. Complications were predominantly Grade 1, with one case of acute urinary retention (2.4%). Ejaculatory function was preserved in 75.6% of patients. Conclusion iTind is a safe and effective minimally invasive option for BPH-related LUTS, providing durable symptom relief with minimal morbidity and high rates of ejaculatory function preservation in a real-world UK setting.